Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

735 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Madjd Z, et al. Among authors: ellis io. Int J Cancer. 2005 Nov 1;117(2):248-55. doi: 10.1002/ijc.21163. Int J Cancer. 2005. PMID: 15900607
P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
Dixon AR, Bell J, Ellis IO, Elston CW, Blamey RW. Dixon AR, et al. Among authors: ellis io. Br J Cancer. 1992 Sep;66(3):537-41. doi: 10.1038/bjc.1992.309. Br J Cancer. 1992. PMID: 1355661 Free PMC article.
p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO. Poller DN, et al. Among authors: ellis io. Br J Cancer. 1992 Sep;66(3):583-8. doi: 10.1038/bjc.1992.318. Br J Cancer. 1992. PMID: 1355662 Free PMC article.
The Nottingham Prognostic Index in primary breast cancer.
Galea MH, Blamey RW, Elston CE, Ellis IO. Galea MH, et al. Among authors: ellis io. Breast Cancer Res Treat. 1992;22(3):207-19. doi: 10.1007/BF01840834. Breast Cancer Res Treat. 1992. PMID: 1391987
Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.
Robertson JF, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW. Robertson JF, et al. Among authors: ellis io. Breast Cancer Res Treat. 1992;22(3):221-7. doi: 10.1007/BF01840835. Breast Cancer Res Treat. 1992. PMID: 1391988
Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment.
Low SC, Dixon AR, Bell J, Ellis IO, Elston CW, Robertson JF, Blamey RW. Low SC, et al. Among authors: ellis io. Br J Surg. 1992 Dec;79(12):1314-6. doi: 10.1002/bjs.1800791224. Br J Surg. 1992. PMID: 1486427 Clinical Trial.
Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up.
Robertson JF, Ellis IO, Elston CW, Blamey RW. Robertson JF, et al. Among authors: ellis io. Eur J Cancer. 1992;28A(4-5):908-10. doi: 10.1016/0959-8049(92)90148-u. Eur J Cancer. 1992. PMID: 1524922 Clinical Trial.
Cellular effects of tamoxifen in primary breast cancer.
Robertson JF, Ellis IO, Nicholson RI, Robins A, Bell J, Blamey RW. Robertson JF, et al. Among authors: ellis io. Breast Cancer Res Treat. 1992 Jan;20(2):117-23. doi: 10.1007/BF01834641. Breast Cancer Res Treat. 1992. PMID: 1554887
Silver-stained nucleolar organiser region counts are of no prognostic value in primary breast cancer.
Sacks NP, Robertson JF, Ellis IO, Nicholson RI, Crocker J, Blamey RW. Sacks NP, et al. Among authors: ellis io. Eur J Surg Oncol. 1992 Apr;18(2):98-102. Eur J Surg Oncol. 1992. PMID: 1582518
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival.
Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO. Locker AP, et al. Among authors: ellis io. Eur J Surg Oncol. 1992 Jun;18(3):224-9. Eur J Surg Oncol. 1992. PMID: 1607032
735 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback